Showing results (11-20 of 160) with videos related to
Sort By:
Pageof 16
Seminars in Neurology|April 27, 2016
Promising Oral Compounds for the Treatment of Multiple Sclerosis: A Glance into the FutureBernhard F Décard, Tobias DerfussNature Reviews. Drug Discovery|September 11, 2024
Targeting cytokine networks in neuroinflammatory diseasesBurkhard Becher, Tobias Derfuss, Roland LiblauJournal of Neurology|March 18, 2005
Intrathecal antibody (IgG) production against human herpesvirus type 6 occurs in about 20% of multiple sclerosis patients and might be linked to a polyspecific B-cell responseTobias Derfuss, Reinhard Hohlfeld, Edgar MeinlPresse Medicale (Paris, France : 1983)|May 25, 2021
Update on treatment in multiple sclerosisIlaria Callegari, Tobias Derfuss, Edoardo GalliCurrent Neurology and Neuroscience Reports|July 27, 2011
Fingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directionsMatthias Mehling, Ludwig Kappos, Tobias DerfussNeurodegenerative Disease Management|August 30, 2017
Daclizumab for the treatment of multiple sclerosisAthina Papadopoulou, Tobias Derfuss, Till SprengerNeurology(R) Neuroimmunology & Neuroinflammation|August 18, 2020
Lymphocyte recovery after fingolimod discontinuation in patients with MSSara Nagy, Jens Kuhle, Tobias DerfussSeminars in Neurology|May 28, 2013
Natalizumab therapy for multiple sclerosisTobias Derfuss, Jens Kuhle, Raija Lindberg, et al.Journal of Molecular Medicine (Berlin, Germany)|May 7, 2010
Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injuryTobias Derfuss, Chris Linington, Reinhard Hohlfeld, et al.Nature Reviews. Neurology|October 10, 2012
B cells and antibodies in multiple sclerosis pathogenesis and therapyMarkus Krumbholz, Tobias Derfuss, Reinhard Hohlfeld, et al.Pageof 16